Meanwhile, new immunotherapeutic treatments, such as programmed cell death protein 1 (PD-1) inhibitors, are being studied for the potential improvement in therapeutic response in patients with multiple myeloma and spinal cord compression [27]. Here, PDCD1 is linked to AL amyloidosis.